BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 30028995)

  • 21. Hedgehog pathway inhibitor HhAntag691 is a potent inhibitor of ABCG2/BCRP and ABCB1/Pgp.
    Zhang Y; Laterra J; Pomper MG
    Neoplasia; 2009 Jan; 11(1):96-101. PubMed ID: 19107236
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CC-115, a Dual Mammalian Target of Rapamycin/DNA-Dependent Protein Kinase Inhibitor in Clinical Trial, Is a Substrate of ATP-Binding Cassette G2, a Risk Factor for CC-115 Resistance.
    Beebe J; Zhang JT
    J Pharmacol Exp Ther; 2019 Nov; 371(2):320-326. PubMed ID: 31455631
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ABCB1 and ABCG2 Overexpression Mediates Resistance to the Phosphatidylinositol 3-Kinase Inhibitor HS-173 in Cancer Cell Lines.
    Wu CP; Hung CY; Hsieh YJ; Murakami M; Huang YH; Su TY; Hung TH; Yu JS; Wu YS; Ambudkar SV
    Cells; 2023 Mar; 12(7):. PubMed ID: 37048130
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ACY 1215, a histone deacetylase 6 inhibitor, inhibits cancer cell growth in melanoma.
    Wang F; Zhong BW; Zhao ZR
    J Biol Regul Homeost Agents; 2018; 32(4):851-858. PubMed ID: 30043566
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine.
    Cosenza M; Civallero M; Marcheselli L; Sacchi S; Pozzi S
    Apoptosis; 2017 Jun; 22(6):827-840. PubMed ID: 28315173
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Coexpression of ABCB1 and ABCG2 in a Cell Line Model Reveals Both Independent and Additive Transporter Function.
    Robinson AN; Tebase BG; Francone SC; Huff LM; Kozlowski H; Cossari D; Lee JM; Esposito D; Robey RW; Gottesman MM
    Drug Metab Dispos; 2019 Jul; 47(7):715-723. PubMed ID: 31048454
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Derivative of 5-cyano-6-phenylpyrimidin antagonizes ABCB1- and ABCG2-mediated multidrug resistance.
    Wang JQ; Wang B; Lei ZN; Teng QX; Li JY; Zhang W; Ji N; Cai CY; Ma LY; Liu HM; Chen ZS
    Eur J Pharmacol; 2019 Nov; 863():172611. PubMed ID: 31476282
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human ATP-Binding Cassette Transporter ABCG2 Confers Resistance to CUDC-907, a Dual Inhibitor of Histone Deacetylase and Phosphatidylinositol 3-Kinase.
    Wu CP; Hsieh YJ; Hsiao SH; Su CY; Li YQ; Huang YH; Huang CW; Hsieh CH; Yu JS; Wu YS
    Mol Pharm; 2016 Mar; 13(3):784-94. PubMed ID: 26796063
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro, in vivo and ex vivo.
    Yang K; Chen Y; To KK; Wang F; Li D; Chen L; Fu L
    Exp Mol Med; 2017 Mar; 49(3):e303. PubMed ID: 28303028
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tivozanib reverses multidrug resistance mediated by ABCB1 (P-glycoprotein) and ABCG2 (BCRP).
    Yang D; Kathawala RJ; Chufan EE; Patel A; Ambudkar SV; Chen ZS; Chen X
    Future Oncol; 2014 Aug; 10(11):1827-41. PubMed ID: 24295377
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tepotinib reverses ABCB1-mediated multidrug resistance in cancer cells.
    Wu ZX; Teng QX; Cai CY; Wang JQ; Lei ZN; Yang Y; Fan YF; Zhang JY; Li J; Chen ZS
    Biochem Pharmacol; 2019 Aug; 166():120-127. PubMed ID: 31078601
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ribociclib shows potential for pharmacokinetic drug-drug interactions being a substrate of ABCB1 and potent inhibitor of ABCB1, ABCG2 and CYP450 isoforms in vitro.
    Sorf A; Hofman J; Kučera R; Staud F; Ceckova M
    Biochem Pharmacol; 2018 Aug; 154():10-17. PubMed ID: 29673999
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics.
    Laino AS; Betts BC; Veerapathran A; Dolgalev I; Sarnaik A; Quayle SN; Jones SS; Weber JS; Woods DM
    J Immunother Cancer; 2019 Feb; 7(1):33. PubMed ID: 30728070
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Jadomycins are cytotoxic to ABCB1-, ABCC1-, and ABCG2-overexpressing MCF7 breast cancer cells.
    Issa ME; Hall SR; Dupuis SN; Graham CL; Jakeman DL; Goralski KB
    Anticancer Drugs; 2014 Mar; 25(3):255-69. PubMed ID: 24231527
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis.
    Cotte S; von Ahsen N; Kruse N; Huber B; Winkelmann A; Zettl UK; Starck M; König N; Tellez N; Dörr J; Paul F; Zipp F; Lühder F; Koepsell H; Pannek H; Montalban X; Gold R; Chan A
    Brain; 2009 Sep; 132(Pt 9):2517-30. PubMed ID: 19605531
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma.
    Vogl DT; Raje N; Jagannath S; Richardson P; Hari P; Orlowski R; Supko JG; Tamang D; Yang M; Jones SS; Wheeler C; Markelewicz RJ; Lonial S
    Clin Cancer Res; 2017 Jul; 23(13):3307-3315. PubMed ID: 28053023
    [No Abstract]   [Full Text] [Related]  

  • 37. Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death.
    Mishima Y; Santo L; Eda H; Cirstea D; Nemani N; Yee AJ; O'Donnell E; Selig MK; Quayle SN; Arastu-Kapur S; Kirk C; Boise LH; Jones SS; Raje N
    Br J Haematol; 2015 May; 169(3):423-34. PubMed ID: 25709080
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Foretinib, a c-MET receptor tyrosine kinase inhibitor, tackles multidrug resistance in cancer cells by inhibiting ABCB1 and ABCG2 transporters.
    Nazari S; Mosaffa F; Poustforoosh A; Mortazavi M; Saso L; Firuzi O; Moosavi F
    Toxicol Appl Pharmacol; 2024 Mar; 484():116866. PubMed ID: 38367674
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Novel Synthetic Dihydroindeno[1,2-b] Indole Derivative (LS-2-3j) Reverses ABCB1- and ABCG2-Mediated Multidrug Resistance in Cancer Cells.
    Guo C; Liu F; Qi J; Ma J; Lin S; Zhang C; Zhang Q; Zhang H; Lu R; Li X
    Molecules; 2018 Dec; 23(12):. PubMed ID: 30544754
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PCI29732, a Bruton's Tyrosine Kinase Inhibitor, Enhanced the Efficacy of Conventional Chemotherapeutic Agents in ABCG2-Overexpressing Cancer Cells.
    Ge C; Wang F; Cui C; Su X; To KKW; Wang X; Zhang H; Song X; Fu L
    Cell Physiol Biochem; 2018; 48(6):2302-2317. PubMed ID: 30114704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.